|Classification and external resources|
|Patient UK||Brugia malayi|
Brugia malayi is a nematode (roundworm), one of the three causative agents of lymphatic filariasis in humans. Lymphatic filariasis, also known as elephantiasis, is a condition characterized by swelling of the lower limbs. The two other filarial causes of lymphatic filariasis are Wuchereria bancrofti and Brugia timori, which both differ from B. malayi morphologically, symptomatically, and in geographical extent.
B. malayi is transmitted by mosquitoes and is restricted to South and South East Asia. It is one of the tropical diseases targeted for elimination by the year 2020 by the World Health Organization, which has spurred vaccine and drug development, as well as new methods of vector control.
- 1 History of discovery
- 2 Transmission: vectors and reservoirs
- 3 Life cycle
- 4 Morphology
- 5 Symptoms
- 6 Laboratory diagnosis
- 7 Management and therapy
- 8 Prevention strategies
- 9 Epidemiology
- 10 Genome deciphered
- 11 See also
- 12 References
- 13 External links
History of discovery
Identification of a distinct parasite
Lichtenstein and Brug first recognized B. malayi as a distinct pathogen in 1927. They reported the occurrence of a species of human filariae in North Sumatra that was both physiologically and morphologically distinct from the W. bancrofti microfilariae commonly found in Jakarta and named the pathogen Filaria malayi. However, despite epidemiological studies identifying Filaria malayi in India, Sri Lanka, China, North Vietnam, and Malaysia in the 1930s, Lichtenstein and Brug’s hypothesis was not accepted until the 1940s, when Rao and Mapelstone identified two adult worms in India.
Based on the similarities with W. bancrofti, Rao and Mapelstone proposed to call the parasite Wuchereria malayi In 1960, however, Buckley proposed to divide the old genus Wuchereria, into two genera, Wuchereria and Brugia and renamed Filaria malayi as Brugia malayi. Wuchereria contains W. bancrofti, which so far has only been found to infect humans, and the Brugia genus contains B. malayi, which infects humans and animals, as well as other zoonotic species.
Identification of different strains
In 1957, two subspecies of human infecting B. malayi were discovered by Turner and Edeson in Malaysia based on the observation of different patterns of microfilaria periodicity. Periodicity refers to a pronounced peak in microfilariae count during a 24‑hour interval when microfilariae are present and detectable in the circulating blood. The basis for this phenomenon remains largely unknown.
- Nocturnal periodicity: microfilariae are not detectable in the blood for the majority of the day, but the microfilarial density peaks between midnight and 2 AM nightly.
- Nocturnal subperiodicity: microfilariae are present in the blood at all times, but appear at greatest density between noon and 8 PM.
Transmission: vectors and reservoirs
B. malayi is transmitted by a mosquito vector. The principal mosquito vectors include Mansonia, Anopheles, and Aedes mosquitoes. The mosquito serves as a biological vector – it is required for the developmental cycle of the parasite (see Life Cycle). The geographical distribution of the disease is thus dependent on suitable mosquito breeding habitat.
- The nocturnal periodic form is transmitted by Mansonia and some Anopheline mosquitoes in open swamps and rice growing areas. These mosquitoes tend to bite at night and appear to only infect humans. Natural animal infections are rare and experimental animals do not retain infection.
- The nocturnal subperiodic form is transmitted by Mansonia in forest swamps, where mosquitoes bite in the shade at any time. Natural zoonotic infections are common. Cats, dogs, monkeys, slow lorises, civet cats, and hamsters have all been successfully experimentally infected with B. malayi from man and may serve as important reservoirs.
The accumulation of many infective mosquito bites—several hundreds to thousands—is required to establish infection. This is because a competent mosquito usually transmits only a few infective L3 larvae (see Life Cycle), and less than 10% of those larvae progress through all the necessary molting steps and develop into adult worms that can mate. Thus those at greatest risk for infection are individuals living in endemic areas—short term tourists are unlikely to develop lymphatic filariasis.
Development and replication of B. malayi occurs in two discrete phases: in the mosquito vector and in the human. Both stages are essential to the life cycle of the parasite.
Mosquito: The mosquito serves as a biological vector and intermediate host – it is required for the developmental cycle and transmission of B. malayi.
4. The mosquito takes a human blood meal and ingests microfilariae (worm-like sheathed eggs) that circulate in the human blood stream.
5-7 In the mosquito, the microfilariae shed sheaths, penetrate the midgut, and migrate to the thoracic muscles were the microfilariae increase in size, molt, and develop into infective larvae (L1 and L3) over a span of 7–21 days. No multiplication or sexual reproduction of microfilariae occurs in the mosquito.
8-1 The infective larvae (L3) migrate to the salivary glands, enter the proboscis and escape onto human skin when the mosquito takes another blood meal.
Human: B. malayi undergoes further development in the human as well as sexual reproduction and egg production.
1-2 The infective larvae (L3) actively penetrate the skin through the bite hole and develop into adults in the lymphatic system over a span of 6 months. Adult worms can survive in the lymphatic system for 5–15 years 
3. The male and female adult worms mate and the females produce an average of 10,000 sheathed eggs (microfilaria) daily  The microfilariae enter the blood stream and exhibit the classic nocturnal periodicity and subperiodicity.
4. Another mosquito takes a blood meal and ingests the microfilariae. Infection depends on the mosquito taking a blood meal during a periodic episode – when microfilariae are present in the bloodstream.
Adult worms resemble the classic nematode roundworm. Long and threadlike, B. malayi and other nematode possess only longitudinal muscles and move in an S-shape motion. Adults are typically smaller than adult W. bancrofti, though few adults have been isolated. Female adult worms (50 mm) are larger than male worms (25 mm).
B. malayi microfilariae are 200-275 um in length and have a round anterior end and a pointed posterior end. The microfilariae are sheathed, which stains heavily with Giemsa. The sheath is actually the egg shell, a thin layer that surrounds the egg shell as the microfilariae circulates in the bloodstream. The microfilariae retain the sheath until it is digested in the mosquito midgut.
B. malayi microfilariae resemble W. bancrofti and Loa loa microfilariae with minor differences that can aid in laboratory diagnosis. B. malayi microfilariae can be distinguished by the noncontinuous row of nuclei found in the tip of the tail. There are two terminal nuclei that are distinctly separated from the other nuclei in the tail, whereas the tail of W. bancrofti contains no nuclei and Loa loa microfilariae nuclei form a continuous row in the tail. B. malayi microfilariae also have a characteristic cephalic space ratio of 2:1.
B. malayi is one of the causative agents of lymphatic filariasis, a condition marked by infection and swelling of the lymphatic system. The disease is primarily caused by the presence of worms in the lymphatic vessels and the resulting host response. Signs of infection are typically consistent with those seen in bancroftian filariasis—fever, lymphadenitis, lymphangitis, lymphedema, and secondary bacterial infection—with a few exceptions.
Lymphadenitis, the swelling of the lymph nodes, is a commonly recognized symptom of many diseases. An early manifestation of filariasis, lymphadenitis more frequently occurs in the inguinal area during B. malayi infection and can occur before the worms mature.
Lymphangitis is the inflammation of the lymphatic vessels in response to infection. It occurs early in the course of infection in response to worm development, molting, death, or bacterial and fungal infection. The affected lymphatic vessel becomes distended and tender, and the overlying skin becomes erythemous and hot. Abscess formation and ulceration of the affected lymph node occasionally occurs during B. malayi infection, more readily than in Bancroftian filariasis. Remnants of adult worms can sometimes be found in the ulcer drainage.
The most obvious sign of infection, elephantiasis, is the enlargement of the limbs. A late complication of infection, elephantiasis is a form of lymphedema and is caused by repeated inflammation of the lymphatic vessels. Repeated inflammatory reactions causes vessel dilation and thickening of the affected lymphatic vessels, which can compromise function. The lymphatic system normally functions to maintain fluid balance between tissues and the blood and serves as an integral part of the immune system. Blockage of these vessels due to inflammatory induced fibrosis, dead worms, or granulomatous reactions can interfere with normal fluid balance, thus leading to swelling in the extremities. Elephantiasis resulting from B. malayi infection typically affects the distal portions of the extremities. Unlike bancroftian filariasis, B. malayi rarely affects genitalia and does not cause funiculitis, orchitis, epididymitis, hydrocele, or chyuria, conditions more readily observed with bancroftian infection.
Secondary bacterial infection
Secondary bacterial infection is common among patients with filariasis. Compromised immune function due to lymphatic damage in addition to lymph node ulcerations and abscesses exposure and impaired circulation due to elephantiasis can cause secondary bacterial or fungal infection. Elephantiasis, in addition to the physical burden of a swollen limb, can be a severely dehabilitating condition given bacterial infection. Part of the WHO’s "Strategy to Eliminate Lymphatic Filariasis" targets hygiene promotion programs in order to alleviate the suffering of affected individuals (see Prevention Strategies).
However, clinical manifestations of infection are variable and depend on several factors, including host immune system, infectious dose, and parasite strain differences. Most infections appear asymptomatic, yet vary from individual to individual. Individuals living in endemic areas with microfilaremia may never present with overt symptoms, whereas in other cases, only a few worms can exacerbate a severe inflammatory response.
The development of the disease in humans, however, is not well understood. Adults typically develop worse symptoms, given the long exposure time required for infection. Infection may occur during childhood, but the disease appears to take many years to manifest. The incubation period for infection ranges from 1 month to 2 years and typically microfilariae appear before overt symptoms. Lymphedema can develop within six months and development of elephantiasis has been reported within a year of infection among refugees, who are more immunologically naive. Men tend to develop worse symptoms than women.
Tender or enlarged inguinal lymph nodes or swelling in the extremities can alert physicians or public health officials to infection.
With appropriate laboratory equipment, microscopic examination of differential morphological features of microfilariae in stained blood films can aid diagnosis—in particular the examination of the tail portion, the presence of a sheath, and the size of the cephalic space. Giemsa staining will uniquely stain B. malayi sheath pink. However, blood films can prove difficult given the nocturnal periodicity of some forms of B. malayi.
PCR based assays are highly sensitive and can be used to monitor infections both in the human and the mosquito vector. However, PCR assays are time-consuming, labor-intensive and require laboratory equipment. Lymphatic filariasis mainly affects the poor, who live in areas without such resources.
The ICT antigen card test is widely used in the diagnosis of W. bancrofti, but commercial antigens of B. malayi have not been historically widely available. However, new research developments have identified a recombinant antigen (BmR1) that is both specific and sensitive in the detection of IgG4 antibodies against B. malayi and B. timori in ELISA and immunochromatographic rapid dipstick (Brugia Rapid) test. However, it appears that immunoreactivity to this antigen is variable in individuals infected with other filarial nematodes. This research has led to the development of two new rapid immunochromatographic IgG4 cassette tests—WB rapid and panLF rapid—which detect bancroftian filariasis and all three species of lymphatic filariasis, respectively, with high sensitivity and selectivity.
Management and therapy
The ["Global Alliance to Eliminate Lymphatic Filariasis"] was launched by the World Health Organization in 2000 with two primary goals: 1) to interrupt transmission and 2) to alleviate the suffering of affected individuals. Mass drug treatment programs are the main strategy for interrupting parasite transmission, and morbidity management, focusing on hygiene, improves the quality of life of infected individuals.
A goal of community base efforts is to eliminate microfilariae from the blood of infected individuals in order to prevent transmission to the mosquito. This is primarily accomplished through the use of drugs. The treatment for B. malayi infection is the same as for bancroftian filariasis. Diethylcarbamazine (DEC) has been used in mass treatment programs in the form of DEC-medicated salt, as an effective microfilaricidal drug in several locations, including India. While DEC tends to cause adverse reactions like immediate fever and weakness, it is not known to cause any long-term adverse drug effects. DEC has been shown to kill both adult worms and microfilariae. In Malaysia, DEC dosages (6 mg/kg weekly for 6 weeks; 6 mg/kg daily for 9 days) reduced microfilariae by 80% for 18–24 months after treatment in the absence of mosquito control. Microfilariae numbers slowly return many months after treatment, thus requiring multiple drug doses over time in order to achieve long-term control. However, it is not known how many years of mass drug administration is required to eliminate transmission. But currently, there have been no confirmed cases of DEC resistance.
Single doses of two drugs (albendazole-DEC and albendazole-ivermectin) have been shown to remove 99% of microfilariae for a year after treatment and help to improve elephantiasis during early stages of the disease. Ivermectin does not appear to kill adult worms but serves as a less toxic microfilaricide.
Since the discovery of the importance of Wolbachia bacteria in the lifecycle of B. malayi and other nematodes, novel drug efforts have targeted the endobacterium. Tetracyclines, rifampicin, and chloramphenicol have been effective in vitro by interfering with larvae molting and microfilariae development. Tetracyclines have been shown to cause reproductive and embryogenesis abnormalities in the adult worms, resulting in worm sterility. Clinical trials have demonstrated the successful reduction of Wolbachia and microfilariae in onchocerciasis and W. bancrofti infected patients. These antibiotics, while acting through a slightly more indirect route, are promising antifilarial drugs.
Secondary bacterial infection is often observed with lymphatic filariasis. Rigorous hygiene practices, including washing with soap and water daily and disinfecting wounds can help heal infected surfaces, and slow and potentially reverse existing tissue damage. Promoting hygiene is essential for lymphatic filariasis patients given the compromised immune and damaged lymphatic systems and can help prevent suffering and disability.
There is currently no licensed vaccine to prevent lymphatic filariasis. However, recent research has produced vaccine candidates with good results in experimental animals. A glutathione-S-transferase, a detoxification enzyme in parasites isolated from Setaria cervi, a bovine filarial parasite, reduced B. malayi adult parasite burden by more than 82% 90 days post parasite.
Vector control has been effective in virtually eliminating lymphatic filariasis in some regions, but vector control combined with chemotherapy produces the best results. It is suggested that 11–12 years of effective vector control may eliminate lymphatic filariasis. Successful methods of B. malayi vector control include residual house spraying using DDT and insecticide treated bednets. Mansonia larvae attach their breathing tubes to underwater roots and plants in order to survive. While chemical larvicides have only provided partial control, plant removal would prevent vector development, but would have potential adverse effects on the aquatic environment. Lymphatic filariasis vector control is neglected in comparison to the far more established efforts to control malaria and Dengue vectors. Integrated vector control methods should be applied in areas where the same mosquito species is responsible for transmitting multiple pathogens.
B. malayi infects 13 million people in south and southeast Asia and is responsible for nearly 10% of the world’s total cases of lymphatic filariasis. B. malayi infection is endemic or potentially endemic in 16 countries, where it is most common in southern China and India, but also occurs in Indonesia, Thailand, Vietnam, Malaysia, the Philippines, and South Korea. The distribution of B. malayi overlaps with W. bancrofti in these regions, but does not coexist with B. timori. Regional foci of endemicity are determined in part by the mosquito vectors (see Transmission).
On September 20, 2007, scientists sequenced the genome of Brugia malayi in the paper "Draft Genome for the Filarial Nematode Parasite Brugia malayi" by Elodie Ghedin, et al. Science 317, 1756 (2007); doi:10.1126/science.1145406. Identifying the genes of this organism might lead to development of new drugs and vaccines.
To decipher the genome, "Whole Genome Shotgun Sequencing" was performed. The genome was found to be approximately 90-95 mega bases in size. The results of the sequencing was then compared to that of the reference nematode Caenorhabditis elegans, along with its prototype Caenorhabditis briggsae. These two other organisms were incorporated in the study and proved to be important for several reasons:
- comparing genomes using C. elegans was extremely beneficial in identifying similar linkages in genes.
- the researchers found a genomic conservation
- also found data that supported an absence of conservation at a more local gene level
- This demonstrated that rearrangements had occurred over time between the C. elegans and B. malayi and allowed researchers to identify genes or proteins that were more specific to B. malayi
- These unique genes were significant because they could have led to the parasitism seen in B. malayi, and would therefore be seen as appropriate targets for future studies.
- gene linkages offer new insight into the evolutionary trend of parasitic genes that could possess clues to further explain their unique ability to successfully survive for many years in human hosts.
Potential for new drugs to treat B. malayi
Sequence comparisons between the two genomes allow us to map C. elegans orthologs to B. malayi genes. Using these orthology mappings (between C. elegans and B.malayi) and by incorporating the extensive genomic and functional genomic data, including genome-wide RNAi screens, that already exist for C. elegans, we identify potentially essential genes in B. malayi. Scientists are hoping to be able to use these genes as potential new drug targets for new drug treatments. The longevity of this parasite complicates treatment because existing drugs target the larvae and, thus, do not completely kill the worms. The drugs often must be taken periodically for years, and the worm can cause a massive immune reaction when it dies and releases foreign molecules in the body. Drug treatments for filariasis have not changed significantly in over 20 years, and with the risk of resistance rising, there is an urgent need for the development of new anti-filarial drug therapies. From the genome sequence, Dr. Ghedin and her co-investigators identified several metabolic pathways containing dozens of gene products that they believe are likely to be helpful for the discovery of more targeted and effective drug therapies.
- Possible new drug targets include:
- nuclear receptors
- collagens and collagen processing
- neuronal signaling
- the B. malayi kinome
- reliance on host (B. malayi) and endosymbiont (Wolbachia) metabolism.
These potential new targets for drugs or vaccines should provide new opportunities for understanding, treating and preventing elephantiasis.
Endosymbiotic relationship of Brugia malayi with Wolbachia
The relationship between the bacteria Wolbachia and B. malayi is not fully understood. Some theories based on research done with Wuchereria bancrofti, another worm that causes filariasis, believe that Wolbachia may: aid in embryogenesis of the worm, be responsible for potent inflammatory responses from macrophages and filarial disease, and may be linked to the onset of lyphodema and blindness sometimes associated with B. malayi infections. According to a study done by University of Bonn in Ghana, doxycycline was effective in depleting Wolbachia from W. bancrofti. It is likely that the mechanism of doxycycline is similar to that in other filarial species, i.e., a predominant blockade of embryogenesis, leading to a decline of microfilariae according to their half-life. This could render doxycycline treatment an additional tool for the treatment of microfilaria-associated diseases in bancroftian filariasis, along with B. malayi fiariasis. The doxycycline course of treatment would be much shorter as it would be able to target the adult worm rather than the larvae current treatments kill, and there would be fewer side effects for the infected individual.
Genome use in transplant research
Another hopeful use for the research is in the area of transplant research. Because the B. malayi genome is the first parasitic genome to have been sequenced, the implications on the mechanism of parasitism in humans are crucial to understand. According to Alan L. Scott, Ph.D., a collaborator at Johns Hopkins University, understanding how a particular parasite, such as B. malayi, can adapt to humans, may yield medical benefits far beyond treating elephantiasis. According to the author, "This worm can reside in the host for years and not necessarily cause disease, in fact the less disease the individual has, the more worms there are in circulation. Now that we know those genes don't exist in humans we can target them to control disease." Some of the predicted proteins for these new genes appear similar to known immuno-modulator proteins, regulators of the immune system, suggesting that they are involved in deactivating the host's immune system to ensure the parasite remains undetected. Knowledge of these previously unknown immune suppressors could also be of use in organ transplants and to help treat autoimmune disease.
According to the Filarial Genome Project being done by The Special Programme for Research and Training in Tropical Diseases (TDR), the Brugia malayi MIF gene is expressed in all life-cycle stages of the parasite, and results suggest that B. malayi MIF may interact with the human immune system during the course of infection by altering the function of macrophages in the infected individual. TDR also states that studies are currently testing the hypothesis that MIF may be involved in reducing the host’s immune response to the filarial parasite. Understanding how this particular parasite has adapted to humans may help organ transplant researchers by figuring out how to prevent the immune system from attacking the transplanted tissue.
Overall hope for the use of the genome sequencing
The genomic information gives us a better understanding of what genes are important for different processes in the parasite’s life cycle. So, it will now be possible to target these genes more specifically and interrupt its life cycle. And, understanding how this particular parasite has adapted to humans may yield medical benefits far beyond treating elephantiasis, says collaborator Alan L. Scott, Ph.D., of the Bloomberg School of Public Health at Johns Hopkins University. "Parasitic worms are a lot like foreign tissue that has been transplanted into the human body. But unlike baboon hearts or pig kidneys, which the immune system quickly recognizes as foreign and rejects, worms can survive for years in the body. Discovering how they do so may someday benefit transplant surgery," explained Dr. Scott.
- Johhn, David T., and William A. Petri. Markell and Voge's Medical Parasitology. 9th ed. St. Louis: Saunders Elsevier, 2006.
- Sasa, Manabu (1979). "A review on classification and geographic distribution on brugian filariasis" (PDF). Joint WPRO/SEARO Working Group on Brugian Filariasis. World Health Organizatioin.
- Shiyung, Liu (2006). "Filaria and plasmodium: distribution of endemic diseases and western plain exploitation in Taiwan" (PDF). XIV International Economic History Congress, Helsinki 2006, Session 46.
- Edeson, J. F. B. & Wilson, T. (1964), "The epidemiology of filariasis due to Wuchereria Bancrofti and Brugia Malayi", Annual Review Entomology 9: 245–268, doi:10.1146/annurev.en.09.010164.001333.
- John, David T. & Petri, William A. (2006), Markell and Voge's Medical Parasitology (9th ed.), St. Louis: Saunders Elsevier, ISBN 0-7216-4793-6.
- "Gideon Infectious Diseases Online. Brugia Malayi.".
- Fischer, P.; Erickson, S. M.; Fischer, K.; Fuchs, J. F.; Rao, R. U.; Christensen, B. M. & Weil, G. J. (2007), "Persistence of Brugia Malayi DNA in vector and non-vector mosquitoes: implication for xenomonitoring and transmission monitoring of lymphatic filariasis", American Journal of Tropical Medicine Hygiene 76 (3): 502–507
- "Lymphatic Filariasis: Epidemiology and Risk Factors". The Centers for Disease Control and Prevention.
- "Life cycle of Brugia Malayi". The Centers for Disease Control.
- Southwick, Frederick S. (2007), Infectious Disease: A Clinical Short Course (2nd ed.), New York: McGraw Hill Professional, ISBN 978-0-07-147722-2.
- Decraemer, W.; Karanastasi, E.; Brown, D. & Backeljau, T. (2003), "Review of the ultrastructure of the nematode body cuticle and its phylogenetic interpretation", Biological Reviews 78 (3): 465–510, PMID 14558593, doi:10.1017/S1464793102006115.
- "Brugia malayi". Web Atlas of Medical Parasitology.
- "Bench aids for the diagnosis of filarial infections. Plate 2 – Brugia malayi, Brugia timori". World Health Organization. 1997.
- Cross, John H. (1996), "Filarial Nematodes: Lymphatic Filariae Wuchereria Bancrofti and Brugia Malayi", Medical Microbiology (4th ed.), The University of Texas Medical Branch at Galveston. The National Institutes of Health.
- "Lymphatic filariasis", The World Health Organization (World Health Organization).
- Noordin, R.; Itoh, M.; Kimura, E.; Rahman, R.; Ravindran, B.; Mahmud, R.; Supali, T. & Weerasooriya, M. (2007), "Multicentre evaluations of two new rapid IgG4 tests (WB rapid and panLF rapid) for detection of lymphatic filariasis", Filaria Journal 6 (9): 9, PMC 2174453, PMID 17961262, doi:10.1186/1475-2883-6-9.
- Noordin, R.; Aziz, R. & Ravindran, B. (2004), "Homologs of the Brugia malayi diagnostic antigen BmR1 are present in other filarial parasites but induce different humoral immune responses", Filaria Journal 3 (10): 10, PMC 544840, PMID 15627400, doi:10.1186/1475-2883-3-10.
- "Lymphatic filariasis". The World Health Organization.
- Adinarayanan S, Critchley J, Das PK, Gelband H. Diethylcarbamazine (DEC)-medicated salt for community-based control of lymphatic filariasis. Cochrane database of systematic reviews, 2007.
- Rao, R. U. (2005), "Endosymbiotic Wolbachia of parasitic filarial nematodes as drug targets" (PDF), The Indian Journal of Medical Research 122 (3): 199–204, PMID 16251775.
- Rathaur, S.; Yadav, M.; Gupta, S.; Anandharaman, V. & Reddy, Maryada Venkatarami (2008), "Filarial glutathione-S-transferase: a potential vaccine candidate against lymphatic filariasis", Vaccine 26 (32): 4094–4100, PMID 18499308, doi:10.1016/j.vaccine.2008.03.099.
- Remme J.H.F, Feenstra P., Lever P.R., Medici A., Morel C., Noma M., Ramaiah K.D., Richards F., Seketeli A., Schmunis G., van Brakel W.H., and Anna Vassall. Chapter 22. Tropical diseases targeted for elimination: Chagas disease, lymphatic filariasis, onchocerciasis, and leprosy. Book: Disease Control Priorities in Developing Countries.
- Chang, M. S. (2002), "Operational issues in the control of the vectors of Brugia", Annals of Tropical Medicine and Parasitology 96 (2): S71–S76, PMID 12625920, doi:10.1179/000349802125002392.
- "Genome deciphered for elephantiasis-causing worm". Reuters.
- The article is based on the public domain (U.S. Government website) source US Dept. of Health and Human Services / Center for Disease Control: Filariasis
- Brugia_life_cycle_and_adults_in_lymphatics video by R. Rao
- Brugia malayi at UMich
- The Special Programme for Research and Training in Tropical Diseases (TDR). "Functional analysis of Brugia malayi genes". 2004
- University of Pittsburgh. "Researchers reveal genetic secrets of devastating human parasite". 20 September 2007.
- Hoerauf, Achim. "Targeting wolbachia, doxycycline reduces pathology of lymphatic filariasis". 18, September 2006.
- The World Health Organization’s Global Program to Eliminate Lymphatic Filariasis
- The Global Alliance to Eliminate Lymphatic Filariasis
- Gideon Infectious Diseases Online
- Parasite Image Library, Centers for Disease Control